[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"multiple-sclerosis-ms-secondary-progressive\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:multiple-sclerosis-ms-secondary-progressive":31},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,8,0,[8,55,85,114,153,190,223,248],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":32,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":44,"lastUpdatePostDateStruct":45,"startDateStruct":48,"completionDateStruct":50,"leadSponsor":52,"locationsCount":4},"100643835","acute-intermittent-hypoxia-combined-with-gait-training-in-multiple-sclerosis-100643835",false,"NCT07631923","Acute Intermittent Hypoxia Combined With Gait Training in Multiple Sclerosis","Acute Intermittent Hypoxia (AIH) Primed Myoelectric Interface Neurorehabilitation Training (MINT) for Gait Recovery in Multiple Sclerosis","MINT","Inclusion Criteria:\n\n* Diagnosis of clinically definite multiple sclerosis\n* Patient-Determined Disease Steps (PDDS) score between 3 and 6\n* Relapse-free for at least 6 months prior to enrollment\n* Age ≥ 18 years and ≤ 75 years\n* Resting oxygen saturation (SpO₂) ≥ 95% on room air\n* Systolic blood pressure between 85-140 mmHg and diastolic blood pressure between 55-90 mmHg\n* Modified Ashworth Scale (MAS) score ≤ 3 at the ankle and knee\n* Mini-Mental State Examination (MMSE) score ≥ 24\n* Ability to walk at least 10 meters with or without an assistive device\n* Ability to perform active ankle dorsiflexion and plantarflexion\n\nExclusion Criteria:\n\n* Uncontrolled hypertension or hypotension outside the required ranges\n* History of epilepsy or seizures\n* Uncontrolled pulmonary, cardiovascular, or orthopedic disease\n* Premorbid or ongoing major psychiatric illness (e.g., major depression, psychosis)\n* Other neurological disease (e.g., stroke, traumatic brain injury, peripheral neuropathy)\n* Illnesses with potential to cause brain injury\n* Frequent or severe unexplained headaches\n* Pregnancy\n* Implanted medical devices (e.g., pacemakers, intrathecal pumps, brain stimulators)","ALL","18 Years","75 Years",{"count":21,"type":22},35,"ESTIMATED","INTERVENTIONAL",[25],"NA","This interventional, randomized, sham-controlled study will examine whether Acute Intermittent Hypoxia (AIH) delivered immediately before Myoelectric Interface Neurorehabilitation Training (MINT)-based locomotor training improves gait in people with Multiple Sclerosis. The primary objectives are to evaluate changes in gait speed and endurance, with secondary objectives assessing spatiotemporal gait parameters, fatigue, and safety. Participants will receive AIH or sham priming followed by standardized treadmill and\u002For overground gait training, with outcome measures collected before and after the intervention across multiple sessions.",[28,29,30,31],"Multiple Sclerosis","Multiple Sclerosis (MS) - Relapsing-remitting","Multiple Sclerosis (MS) Primary Progressive","Multiple Sclerosis (MS) Secondary Progressive",[33,34,35,36,37,38,39,40,41,42],"hypoxia","neuroplasticity","rehabilitation","gait","recovery","walking","walk","lower extremities","strength","AIH","NOT_YET_RECRUITING","2026-06-02",{"date":46,"type":47},"2026-06-08","ACTUAL",{"date":49,"type":22},"2026-06-15",{"date":51,"type":22},"2028-06-01",{"name":53,"class":54},"Shirley Ryan AbilityLab","OTHER",{"id":56,"slug":57,"hasResults":11,"nctId":58,"briefTitle":59,"officialTitle":60,"acronym":61,"eligibilityCriteria":62,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":63,"enrollmentInfo":64,"targetDuration":4,"studyType":23,"phases":66,"briefSummary":68,"conditions":69,"keywords":70,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":76,"startDateStruct":78,"completionDateStruct":80,"leadSponsor":82,"locationsCount":84},"100610082","phase-2-a-study-of-remibrutinib-using-mr-imaging-in-relapsing-or-progressive-ms-100610082","NCT07222956","A Study of Remibrutinib Using MR Imaging in Relapsing or Progressive MS","An Open-label, Single-center Study of Remibrutinib Using Ultra High-field (7T) MR Imaging in Relapsing or Progressive MS (RemiSeven)","RemiSeven","Inclusion Criteria:\n\nTo be eligible for the study, participants must meet the following eligibility criteria at the Screening visit:\n\n1. Written informed consent signed by participant.\n2. English-speaking.\n3. Male and female participants, 18-60 years of age inclusive.\n4. Established diagnosis of relapsing or progressive MS, as defined by the 2024 revision of McDonald Diagnostic Criteria (any form of MS). A diagnosis of MS must be confirmed at the time of the screening visit.\n5. Expanded Disability Status Score (EDSS) of 0 - 6.5, inclusive.\n6. Adequate vision and motor function to participate in assessment procedures.\n7. Females participating in the study must meet one the following criteria:\n\n   1. Surgically sterilized (e.g., hysterectomy, bilateral oophorectomy or tubal ligation) for at least 6 months or postmenopausal (postmenopausal females must have no menstrual bleeding for at least 1 year) or\n   2. If not postmenopausal, agree to use a double method of contraception, one of which is a barrier method (e.g., intrauterine device plus condom, spermicidal gel plus condom) 30 days prior to dosing until 30 days after last dose and have negative human chorionic gonadotropin (β-hCG) test for pregnancy at screening and at each follow-up visit.\n8. Males who have not had a vasectomy must use appropriate contraception methods (barrier or abstinence) from 30 days prior to dosing until 30 days after last dose.\n9. Evidence of disease activity in the prior 12 months (at least one clinical relapse or one gadolinium enhancing lesion or new T2 lesion) or presence of disability worsening based clinician's assessment in the prior 12 months.\n10. Participants should be in reasonably good health and neurologically stable over the last 1 month (no MS relapse in this period).\n\nExclusion Criteria:\n\nParticipants will be excluded from the study if any of the following exclusion criteria exist at the Screening Visit:\n\n1. Concurrent treatment with any disease modifying therapy for MS or systemic immunotherapy for other autoimmune or rheumatological disorders (e.g. rheumatoid arthritis, systemic lupus erythematosus, inflammatory bowel disease) according to study protocol.\n2. Ongoing substance abuse (drug or alcohol) or any other factor that may interfere with the participant's ability to cooperate and comply with study procedures.\n3. History of malignancy of any organ system (other than complete resection of localized basal cell carcinoma of the skin or in situ cervical cancer) within the past 5 years regardless of treatment or metastasis status.\n4. History of liver disease or liver function abnormalities at baseline including Gilbert syndrome:\n\n   i. Acute or chronic liver disease ii. Cirrhosis iii. Any degree of hepatic impairment (i.e., mild, moderate, or severe) based on Child Pugh classification.\n\n   iv. Untreated hepatitis C or active hepatitis B infection v. Alcohol intake greater than 2 drinks\u002Fday for men and greater than 1 drink per day for women vi. Transaminases (i.e., AST or ALT) \\> 1.5x the upper limit of normal (ULN) vii. Total bilirubin \\>1.5 x ULN viii. Alkaline phosphatase \\> 2x ULN unless caused by non-liver related disorder or explained by a stable chronic liver disorder\n5. History of severe renal disease or creatinine level above 1.5 x upper limit normal.\n6. Pregnancy, planned or current.\n7. History of severe depression or suicidality.\n8. Hematological abnormalities at screening: hemoglobin \\\u003C 10 g\u002Fdl, platelets \\\u003C 100000\u002Fmm3, absolute lymphocyte count \\\u003C 800\u002Fmm3, white blood cells \\\u003C 3000\u002Fmm3, neutrophils \\\u003C 1500\u002Fmm3, B-cell count \\\u003C 50% lower limit of normal, total IgG or total IgM \\\u003C lower limit of normal.\n9. Active clinically significant bacterial, viral, parasitic, or fungal infections, in the judgement of the investigator.\n10. History of significant central nervous system disease (e.g. stroke, traumatic brain injury, myelopathy, progressive multifocal leukoencepahalopathy).\n11. History of splenectomy.\n12. History of active or latent tuberculosis with a positive QuantiFERON, at screening.\n13. Individuals with a known immunodeficiency syndrome, drug-induced immunodeficiency, hereditary immunodeficiency, or who test positive for Human immunodeficiency virus (HIV) antibody, at screening\n14. Clinically significant cardiovascular, renal, hepatic, endocrine, metabolic, hematological, pulmonary, or gastrointestinal disorders that in the investigator's opinion would compromise the safety of the participant or interfere with the interpretation of the study results.\n15. History or current diagnosis of ECG abnormalities such as concomitant clinically significant cardiac arrhythmias, history of familial long QT syndrome, cardiac arrhythmias requiring anti-arrhythmic treatment with class Ia or III anti-arrhythmic drugs.\n16. Resting QT interval corrected by Fridericia's formula (QTcF) \\>450 msec (male) or \\>460 msec (female) prior to screening.\n17. Requirement for anticoagulant medication or use of dual anti-platelet therapy. Use of acetylsalicylic acid up to 100 mg\u002Fday or clopidogrel up to 75 mg\u002Fday, is permitted.\n18. Significant bleeding risk or history of clinically significant bleeding disorders.\n19. Use of gastric acid modifying agents, such as proton pump inhibitors or H2 antagonists.\n20. Use of any strong or moderate inhibitors of CYP3A4 (including clarithromycin, grapefruit, itraconazole, ketoconazole), or strong or moderate inducers of CYP3A4 (including carbamazepine, phenytoin, St John's Wort, primidone, modafinil). Use of BCRP or P-glycoprotein substrates. Use of any herbal\u002Fdietary supplements 8 weeks prior to first dose of study drug or during the study period. Concomitant medicines will be examined on a case-by-case basis against the Flockhart Table by study investigator, and if needed, the Medical Monitor, to determine allowability.\n21. Live vaccines within 6 weeks prior to screening or requirement to receive these vaccinations at any time during study treatment.\n22. Inability to complete MRI with contrast (claustrophobia, pacemaker, cochlear implant, metallic implants incompatible with MR, hypersensitivity to gadolinium-based contrast agent, or severe renal disease).\n23. Subjects who score \"yes\" to items 4 or 5 of the C-SSRS suicidal ideation or any of the items on C-SSRS suicidal behavior section at screening.\n24. Other factors that the Investigator determines would place the individual at risk for participation or interfere with interpretation of the results.","60 Years",{"count":65,"type":22},20,[67],"PHASE2","The study is an investigator-run, study following participants for 2 years with twice-daily remibrutinib. MRI is the main endpoint. Safety, tolerability, and efficacy are secondary endpoints. Approximately 20 participants with relapsing or progressive forms of MS will be recruited.",[29,31,30],[71,72,73,74],"multiple sclerosis","Relapsing","Progressive","Remibrutinib","2026-05-19",{"date":77,"type":47},"2026-05-20",{"date":79,"type":22},"2026-06-30",{"date":81,"type":22},"2030-12-30",{"name":83,"class":54},"Moein Amin",1,{"id":86,"slug":87,"hasResults":11,"nctId":88,"briefTitle":89,"officialTitle":90,"acronym":91,"eligibilityCriteria":92,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":93,"targetDuration":4,"studyType":23,"phases":95,"briefSummary":97,"conditions":98,"keywords":100,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":105,"lastUpdatePostDateStruct":106,"startDateStruct":108,"completionDateStruct":110,"leadSponsor":112,"locationsCount":84},"100638093","phase-1-safety-and-efficacy-of-s103-cells-in-progressiverefractory-multiple-sclerosis-100638093","NCT07587125","Safety and Efficacy of S103 Cells in Progressive\u002FRefractory Multiple Sclerosis","Safety and Efficacy of S103 Cells in Patients With Progressive or Refractory Multiple Sclerosis：An Open-Label, Single-Arm, Exploratory Clinical Study","RESET-MS","Inclusion Criteria:\n\n1. Age ≥18 years and ≤75 years;\n2. The subject signs the informed consent form, is willing and able to comply with the protocol, complete the research assessments and return for follow-up;\n3. To be diagnosed with Multiple Sclerosis (MS) according to the 2017 McDonald criteria, specifically including Progressive MS (Primary Progressive MS \\[PPMS\\] or Secondary Progressive MS \\[SPMS\\]) or Relapsing-Remitting MS (RRMS);\n4. The subject must be assessed by the investigator as having progressive or refractory MS for which no effective standard therapy is available. For subjects with Relapsing MS (RMS), refractory\u002Fprogressive disease is defined as having experienced at least 2 clinical relapses within the past 2 years, or at least 1 clinical relapse within the past 1 year accompanied by at least one gadolinium-enhancing lesion on MRI within the past year, despite treatment with standard disease-modifying therapies (DMTs). In addition, the subject must have an Expanded Disability Status Scale (EDSS) score between 2.0 and 7.0, inclusive, at both screening and baseline;\n5. Male study participants must agree to take contraceptive measures during the treatment period and within 1 year after receiving study treatment, and are prohibited from donating sperm throughout the study period;\n6. Women of childbearing potential (WOCBP) must agree to take contraceptive measures during treatment and for at least 1 year after receiving study treatment. Participants must have a negative serum pregnancy test result during screening; a negative urine pregnancy test result must be confirmed before receiving CAR-T for the first time.\n\nExclusion Criteria:\n\nSubjects will be ineligible for inclusion in the study if they meet any of the following criteria prior to screening or at the baseline visit:\n\n1. The subject has any medical, psychological, or social condition that, in the investigator's opinion, may harm the subject, interfere with their ability to participate in the study, or result in poor protocol compliance;\n2. Female subjects who are pregnant or lactating, plans to become pregnant at any time within 12 months after receiving CAR-T cell treatment, or has a history of spontaneous or induced abortion within 4 weeks prior to screening;\n3. The subject has a clinically relevant active infection, such as sepsis, pneumonia, or a severe local abscess, or a serious infection requiring hospitalization or intravenous antibiotic treatment within 4 weeks prior to screening. Subjects are also excluded if they have a known immunodeficiency disorder including Human Immunodeficiency Virus (HIV), test positive for Hepatitis B surface antigen (HBsAg) or detectable Hepatitis B virus (HBV) DNA, test positive for Hepatitis C virus (HCV) antibody with detectable HCV RNA, test positive for syphilis during the screening period, or have an active or high-risk history of tuberculosis infection;\n4. The subject has previously received any Chimeric Antigen Receptor (CAR) T-cell therapy or other genetically modified cell therapies, or has a history of allogeneic hematopoietic stem cell transplantation (HSCT) or solid organ transplantation. Furthermore, subjects are excluded if they have received intravenous immunoglobulin (IVIG) or plasma exchange (PE) within 4 weeks prior to screening, or have received tocilizumab or eculizumab treatment within 3 months prior to screening;\n5. The subject is diagnosed with an active, severe autoimmune disease other than Multiple Sclerosis, such as Systemic Lupus Erythematosus or Rheumatoid Arthritis. This also includes the presence of other severe progressive neurodegenerative or central nervous system (CNS) disorders, such as Parkinson's disease, Alzheimer's disease, stroke, or active CNS tumors, that the investigator believes would confound the clinical assessment of Multiple Sclerosis. Additionally, a history of active malignancy within the past 5 years excludes the subject, with the exception of adequately treated basal cell or squamous cell carcinoma of the skin, or carcinoma in situ of the cervix;\n6. The subject exhibits specific laboratory abnormalities or organ dysfunction during the screening period, including elevated liver enzymes with AST or ALT greater than 1.5 times the upper limit of normal (ULN), total bilirubin greater than 1.5 times the ULN, or a Creatinine Clearance (CrCl) of less than 60 mL\u002Fmin. Exclusions also apply for an absolute neutrophil count (ANC) of less than 2.0 × 10\\^9\u002FL, a platelet count of less than 100 × 10\\^9\u002FL, hemoglobin levels below 100 g\u002FL, or severe cardiovascular or pulmonary diseases, which include a Left Ventricular Ejection Fraction (LVEF) below 50%, unstable angina or myocardial infarction within the past 6 months, or a resting peripheral blood oxygen saturation (SpO2) of 91% or less;\n7. The subject has a known severe allergy, hypersensitivity, or intolerance to fludarabine, cyclophosphamide, or any excipients contained in the S103 CAR-T cell product, such as human serum albumin. Subjects are also excluded if they have received any live attenuated vaccine within 6 weeks prior to screening, or plan to receive a live vaccine during the study period.",{"count":94,"type":22},9,[96],"PHASE1","This study is a single-center, open-label, single-arm, exploratory clinical study to evaluate the safety, tolerability, and preliminary efficacy of S103（BCMA-CAR T ）cells in the treatment of progressive or refractory multiple sclerosis. The study is a dose escalation trial in adult progressive and refractory MS patients. A standard \"3+3\" design will be used to perform dose escalation to explore the safety profile and dose-limiting toxicities (DLTs). A total of 9 MS patients who meet the inclusion criteria are expected to be recruited.",[30,28,31,99],"Refractory Multiple Sclerosis",[28,101,99,102,103,104],"Progressive Multiple Sclerosis","BCMA-CAR T Cells","Chimeric Antigen Receptor T-Cell Therapy","Safety and Efficacy","2026-05-07",{"date":107,"type":47},"2026-05-14",{"date":109,"type":22},"2026-05",{"date":111,"type":22},"2029-11",{"name":113,"class":54},"Xijing Hospital",{"id":115,"slug":116,"hasResults":11,"nctId":117,"briefTitle":118,"officialTitle":119,"acronym":4,"eligibilityCriteria":120,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":121,"enrollmentInfo":122,"targetDuration":4,"studyType":23,"phases":124,"briefSummary":125,"conditions":126,"keywords":134,"overallStatus":143,"whyStopped":4,"lastUpdateSubmitDate":144,"lastUpdatePostDateStruct":145,"startDateStruct":147,"completionDateStruct":149,"leadSponsor":151,"locationsCount":84},"100599529","phase-1-phase-1-study-of-hbi0101-car-t-in-refractory-b-cell-autoimmune-diseases-100599529","NCT07085676","Phase 1 Study of HBI0101 CAR-T in Refractory B-Cell Autoimmune Diseases","A Phase 1 Dose Escalation and Safety Study of HBI0101 CART in B-cell Mediated Refractory Autoimmune Diseases","Inclusion Criteria:\n\n1. Age: 18\\~80 years old; for patients aged ≥ 75 years, geriatric assessment and endorsement are required;\n2. Diagnosis of B-cell mediated ARDs listed below:\n\n   SLE patients: individuals diagnosed with SLE according to American College of Rheumatology (ACR) and\u002For Systemic lupus international collaborating clinics (SLICC) classification criteria, who have severe and progressive disease course reflected by Systemic Lupus Erythematosus Disease Activity Index-2000 (SLEDAI-2K) score of 8 or more. Eligible patients must have failed to at least one of the conventional DMARDs (azathioprine, methotrexate, mycophenolate mofetil or cyclophosphamide), one of the calcineurin inhibitors (tacrolimus or cyclosporin) and one of the biologic agents (belimumab, rituximab or aniflorumab), each administered for a minimum of 3 months, or have a contraindication to, or have experienced toxicity from, any therapy within these categories. The failure is defined as:\n   * lack of response per SLEDAI-2k (\\\u003C4 points reduction from baseline) or no improvement in BILAG domains, or\n   * disease flare per SLEDAI-2k (≥4 points increase from baseline) or new BILAG A or ≥2 new BILAG B organ scores, or intolerance or discontinuation due to adverse effects.\n\n   SSc patients: Patients who were diagnosed with diffuse or limited cutaneous SSc according to the College of Rheumatology\u002FEuropean Alliance of Associations for Rheumatology (ACR-EULAR) classification criteria, with severe or rapidly progressive disease Eligible patients must meet any of the following criteria:\n   * Progression of skin thickening ≥ 12 over the past 6 months or Modified Rodnan skin score (mRSS) ≥15\n   * Any Medsger Disease Severity Score grade 3-4 in one major organ or grade ≥2 in two organs\n   * Progressive interstitial lung disease evidenced by HRCT or FVC \\\u003C80% or DLCO \\\u003C80%, or evidence of pulmonary function decline, defined as an absolute FVC decline of ≥ 10% , or FVC decline of 5% -9% combined with DLCO 15%.\n   * Other internal organ involvement.\n\n   Eligible patients must have failed to at least two state-of-the-art immunosuppressive therapies including MTX, MMF, cyclophosphamide, azathioprine, nintedanib, tocilizumab or rituximab; each therapy must have been administered for a minimum of 3 months, unless discontinued due to a contraindication or toxicity. The failure is defined as:\n   * lack of response in skin per mRSS (≤20% relative and ≤5 point absolute reduction from baseline) or no clinically meaningful improvement in FVC, DLCO, or other organ involved assessed by Medsger DSS, or\n   * disease flare in skin per mRSS (increase in mRSS ≥20% and ≥5 points from baseline) or decline in FVC ≥10% predicted or in DLCO ≥15% predicted from baseline, other major SSc complication, or\n   * intolerance or discontinuation due to adverse effects\n\n   IIM, including dermatomyositis, anti-synthetase syndrome, immune mediated necrotizing myopathy, and polymyositis: patients must be diagnosed with IIM according to the 2017 ACR\u002FEULAR Classification Criteria for idiopathic inflammatory myopathies.\n\n   Eligible patients must have active disease, defined by at least one of the following:\n   * CPK ≥4xULN\n   * Loss of muscle strength in the weakest muscle group for less than 80% per MMT8\n   * Evidence on MRI of active myositis within last 6 months\n   * Evidence on EMG of active myositis within last 6 months\n   * Muscle biopsy evidence of active myositis within last 6 months\n\n   Only patients with refractory disease will be recruited, defined as previous failure to (1) at least two of five non-glucocorticoids immunosuppressive therapies and (2) either rituximab or IVIG, each administered for a minimum of 3 months, or have a contraindication to, or have experienced toxicity from, any therapy within these categories. The five non-glucocorticoids therapies considered are azathioprine, MTX, MMF, IVIG, and rituximab The failure is defined as:\n   * lack of response in muscle strength per MMT-8 or CPK (\\\u003C20% relative improvement) or per MRI or\n   * disease flare in muscle strength per MMT-8 (≥30% decline) or CPK (≥30% rise) or objective worsening of other organ involvement per Myositis Disease Activity Assessment Tool or\n   * intolerance or discontinuation due to adverse effects\n\n   RA patients: Seropositive RA patients (positive for anti-cyclic citrullinated peptide and rheumatoid factor), diagnosed according to the 2010 ACR\u002FEULAR classification criteria.\n\n   Eligible patients must exhibit high disease activity (DAS28CRP ≥5.1), and be resistant to at least four conventional synthetic and biologic disease-modifying antirheumatic drugs (DMARD) groups.\n\n   Each patient must have previously received at least one medication from each of the mentioned groups, including\n   * JAK-STAT inhibitors\n   * Anti-TNF agents\n   * Anti-IL6 drugs\n   * Anti-CTLA4-Ig treatments, each administered for a minimum of 3 months, or have a contraindication to, or have experienced toxicity from, any therapy within these categories\n\n   Drug resistance is defined as:\n   * Inadequate clinical response measured by composite score DAS28CRP (\\> 3.6) or failure to reach ACR20 or\n   * Disease progression measured by DAS28CRP (≥20% increase) or radiographic progression or\n   * Intolerance or discontinuation due to adverse effects\n\n   NMOSD: Patients must be diagnosis of AQP4-IgG-positive NMOSD based on the 2015 International Panel for NMOSD Diagnosis (IPND) criteria (Wingerchuk et al., 2015).\n\n   Eligible patients must have experienced at least two relapses in the past 24 months, with at least one occurring in the preceding 12 months before screening Each patients must have previously received with inadequate disease control (one or more clinical attacks, with new MRI activity, despite adequate treatment dosing) at least one immunosuppressant for at least 6 months (azathioprine or mycophenolate mofetil) and\u002For Rituximab for at least 3 months and\u002For a targeted therapy (eculizumab, inebilizumab, or satralizumab) or must have a contraindication to such treatment.\n\n   MS patients: must have confirmed history of diagnosis of primary progressive or secondary progressive MS .\n\n   Eligible patients must have: Expanded Disability Status Scale (EDSS) score between 3.0 and 8.5 and evidence of disease activity, defined by either clinical progression and\u002For radiological finding on MRI, such as new, enhancing or enlarging lesions in the last 12 months.\n\n   Eligible patient must have previously received at least one high efficacy drug and have been offered standard treatments and have experienced disease progression or lack of efficacy despite at least six months of treatment. These will include clinical activity (new relapse\\[s\\]), radiological activity (new or enlarging T2 lesions and\u002For gadolinium-enhancing lesions on MRI), or confirmed disability progression (an increase in least 1 point on the EDSS sustained for ≥6 months).\n\n   Eligible patient must have history of treatment with anti-CD20 mAb with continuing evidence of worsening physical disability over a period of ≥6 months, with documented clinical disability progression within the year prior to inclusion, irrespective to concurrent MRI activity.\n\n   MG patients must meet all the following criteria:\n\n   \\- Confirmed diagnosis of generalized MG, supported by positive autoantibodies (anti-AChR, anti-MuSK).\n\n   Disease Severity:\n   * Myasthenia Gravis Activities of Daily Living (MG-ADL) score of ≥6, with ocular symptoms constituting less than 50% of the total score.\n   * Myasthenia Gravis Foundation of America (MGFA) clinical classification of II to IV.\n\n   Eligible patients must have Refractory Status and meet at least one of the following criteria:\n   * No improvement or worsening myasthenic symptoms, with failure to achieve minimal manifestation status or meaningful improvement in MGFA class or MG-ADL score, or recurrent myasthenic exacerbations despite adequate immunosuppressive or immunomodulatory therapy for at least 6 months for all therapies and 3 months for B cell depletion therapy\n   * Improvement in Post-Intervention Status (PIS), but with an MG-ADL score ≥6 persisting for at least 4 months.\n   * Remission or improvement in PIS, but with ≥1 episode of disease exacerbation (MG-ADL ≥6) per year during tapering of immunotherapy medications.\n   * After experiencing a myasthenic crisis, patients who undergo multiple immunotherapies (e.g., intravenous immunoglobulin, plasma exchange, high-dose intravenous methylprednisolone), thymectomy, and active infection control but still cannot be weaned off the ventilator due to MG-induced respiratory muscle weakness for more than 14 days.\n\n   Each patient must receive stable doses of medication prior to enrollment.\n\n   Refractory APLA patients: must have confirmed history of APLA, based on Sydney 2006 or ACR\u002FEULAR 2023 criteria\n\n   \\- Eligible patients must have medium to high-titer antiphospholipid antibodies, documented repeatedly (≥2 tests spanning 12 weeks) Eligible patients must have refractory disease: persistent or recurrent arterial thrombosis, venous thrombosis or diffuse alveolar hemorrhage despite conventional therapy with stable treatment with vitamin K antagonist anticoagulation (maintained at therapeutic stable dose keeping INR consistently within target range) and immunosuppression treatment including glucocorticoid, rituximab and Plaquenil\n3. AST\u002FALT below 5 times the upper limit of normal, blood bilirubin below 3 times the upper limit of normal ;\n4. Cardiopulmonary function is basically normal, echocardiography indicates that the ejection fraction is \\>45%, normal to mild pulmonary hypertension, and the oxygen saturation is above 93% in the resting state without oxygen;\n5. No obvious active infection;\n6. There are no contraindications for blood collection;\n7. Women of child-bearing potential (WCBP), defined as a sexually mature woman who has not undergone a hysterectomy or tubal ligation or who has not been naturally postmenopausal for at least 24 consecutive months, must have a negative serum pregnancy test prior to treatment. All sexually active WCBP and all sexually active male subjects must agree to use effective methods of birth control throughout the study;\n8. Voluntary participation and informed consent signed by the patient or his\u002Fher legal\u002Fauthorized representative.\n9. Ability and willingness to adhere to the study visit schedule and all protocol requirements\n\nExclusion Criteria\n\n1. CNS disease- History of CNS or spinal cord tumor, metabolic or infectious cause of myelopathy, genetically inherited progressive CNS disorder, sarcoidosis, non-autoimmune progressive neurologic condition or PML\n2. Abnormal liver function: aspartate transaminase (AST) or alanine transaminase (ALT) or glutamyl transpeptidase (GGT) or alkaline phosphatase (ALP) detection value is greater than 5 times the upper limit of normal (ULN); or total bilirubin test value greater than 3 times the upper limit of normal (ULN); Exceptional: liver function disturbance due to myositis.\n3. Cardiovascular disease: Unstable angina or myocardial infarction or coronary artery bypass graft (CABG) within 6 months prior to leukapheresis\u002F moderate- severe pulmonary hypertension\u002F severe arrhythmia (ventricular tachycardia, ventricular fibrillation, high grade ventricular block) in the past 6 months; New York heart function class (NYHA) class III- Level IV or LVEF\\\u003C45%.\n4. Lung disease: patients with chronic lung disease with any of the following: \\* Oxygen saturation (SpO2) \\\u003C 90% on room air \\* FVC≤45% of predicted or DLCO≤40% of predicted at screening. \\* Evidence of pulmonary hypertension as defined as estimated RVSP\\> 50 mmHg.\n5. Muscle disease: evidence of any of the following: \\* Severe proximal muscle atrophy of upper or lower extremity on MRI or clinical examination. \\*Finding of muscular inflammation or myopathy other than the indication, such as inclusion body myositis (IBM), or cancer-associated myositis (myositis diagnosed within 2 years of cancer).\n6. Other uncontrolled diseases: acute diseases (such as acute pneumonia or other infection, pulmonary embolism, diabetic ketoacidosis, acute pancreatitis, etc.) that are clinically unstable or have not been effectively controlled and are not related to indicated autoimmune diseases which in the judgment of the investigator may confound study results or place subjects at undue risk.\n7. Biologics therapy: Received rituximab within 4 months of expected CAR T treatment: No plasma exchange or immunoglobulin treatment within 4 weeks prior to screening. MS patients: No high dose corticosteroid treatment in the 30 days prior to enrollment; see also section 9.1 for the list of restrictions.\n8. Participated in any clinical study within 3 months prior to enrollment, or participate in other clinical investigations during the study period.\n9. Previous or concurrent malignancy with the following exceptions: Adequately treated basal cell or squamous cell carcinoma, in situ carcinoma of the cervix or breast, treated curatively and without evidence of recurrence for at least 3 years prior to screening. A primary malignancy which has been completely resected, or treated, and is in complete remission for at least 5 years prior to screening.\n10. Transplantation: History of vital organ transplantation (e.g., heart, lung, kidney, liver) or hematopoietic stem cell\u002For bone marrow transplantation.\n11. Disease-specific criteria: MS\u002FNMO patients: No disease relapse in the 30 days prior to enrollment\n12. Known HIV positive status.\n13. Active hepatitis B or C infection.\n14. Active CMV infection\n15. Pregnant or lactating women.\n16. Inability to understand or follow the research protocol subject requirements.\n17. Have any other clinically significant disease history or current disease that, in the judgment of the research physician, may pose a risk to the safety of the subjects, or interfere with the completion of the research procedure and the evaluation of safety and efficacy","80 Years",{"count":123,"type":22},120,[96],"A Phase 1 study of HBI0101 BCMA-CART in B-Cell Mediated Autoimmune Rheumatic Diseases. The goal of the study is evaluation of safety and identification of the maximum HBI0101 CART dose that may be administered safely to patients with B-cell mediated autoimmune disease.",[127,128,129,130,30,31,131,132,133],"Systemic Sclerosis (SSc)","Idiopathic Inflammatory Myopathy (IIM)","Rheumatoid Arthritis (RA)","Systemic Lupus Erythematosus (SLE)","Neuromyelitis Optica Spectrum Disorder (NMOSD)","Myasthenia Gravis (MG)","Antiphospholipid Antibody Syndrome",[135,130,136,137,138,139,140,141,131,132,142],"B-cell mediated autoimmune rheumatic diseases","Systemic sclerosis (SSC)","Idiopathic inflammatory myopathy (IIM)","Rheumatoid arthritis (RA)","B-cell maturation antigen (BCMA)","Autologous CAR-T","Multiple sclerosis (MS) Primary and Secondary progressive","refractory antiphospholipid antibody syndrome","RECRUITING","2026-04-29",{"date":146,"type":47},"2026-05-06",{"date":148,"type":47},"2024-09-01",{"date":150,"type":22},"2030-11-01",{"name":152,"class":54},"Polina Stepensky",{"id":154,"slug":155,"hasResults":11,"nctId":156,"briefTitle":157,"officialTitle":158,"acronym":159,"eligibilityCriteria":160,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":161,"enrollmentInfo":162,"targetDuration":4,"studyType":23,"phases":164,"briefSummary":165,"conditions":166,"keywords":169,"overallStatus":143,"whyStopped":4,"lastUpdateSubmitDate":179,"lastUpdatePostDateStruct":180,"startDateStruct":182,"completionDateStruct":184,"leadSponsor":186,"locationsCount":189},"100629666","phase-1-treatment-of-participants-with-primary-or-secondary-progressive-multiple-sclerosis-100629666","NCT07477639","Treatment of Participants With Primary or Secondary Progressive Multiple Sclerosis","A Phase 1\u002F2a, Open-Label, Dose-Escalation Study to Evaluate the Safety and Preliminary Efficacy of TRX319 in Subjects With Primary or Secondary Progressive Multiple Sclerosis","IMPACT-MS","Inclusion Criteria:\n\n1. Clinical diagnosis of MS with evidence of PPMS or SPMS according to 2025 McDonald criteria.\n2. Expanded Disability Status Scale (EDSS) range ≥ 2.5 to ≤ 6.5.\n3. Evidence of clinical disability progression within 2 years prior to enrollment.\n4. Documented presence of CSF-restricted OCBs and\u002For elevated IgG index and\u002For κ free light chain.\n5. Males and females ≥ 18 and ≤ 65 years of age at time of consent.\n6. Evidence of adequate organ function\n7. Women of child bearing potential have a negative pregnancy test at screening.\n8. Contraceptive use by all participants while on study.\n9. Participants must be able to understand, consent, and be willing and able to complete all specified procedures and visits.\n10. Positive varicella zoster virus titer. Participants who test seronegative for varicella zoster virus IgG antibodies need to complete vaccination ≥ 4 weeks prior to TRX319 infusion.\n11. Participants must be willing to refrain from donating blood for 1 year after TRX319 infusion.\n\nExclusion Criteria:\n\n1. MS clinical stability on disease modifying therapy.\n2. Clinical relapse of MS in the 1 year prior to study entry.\n3. Diseases other than MS to explain the first demyelinating event, including aquaporin 4 IgG or myelin oligodendrocyte glycoprotein-IgG seropositivity.\n4. Prior treatment with CAR-T or gene therapy product directed at any target.\n5. Prior treatment with mitoxantrone, cladribine (or other chemotherapies), or alemtuzumab within 2 years prior to TRX319 dose.\n6. Prior treatment with CD20-depleting antibodies within 3 months and prior treatment with Bruton's tyrosine kinase inhibitor (BTKi) and sphingosine 1 phosphate (S1P) modulators within 1 month of TRX319 dose.\n7. Plan to or have received live, attenuated vaccines less than 4 weeks (28 days) prior to TRX319 infusion, and other vaccines less than 2 weeks (14 days) prior to TRX319 infusion.\n8. Serologic status reflecting active hepatitis B or C infection.\n9. Positive serology for human immunodeficiency virus (HIV).\n10. History of progressive multifocal leukoencephalopathy.\n11. Untreated active, or active with documented completed treatment but without a negative chest X-ray that shows no evidence of active tuberculosis, or latent tuberculosis.\n12. Primary immunodeficiency as defined by a known genetic disorder.\n13. History of splenectomy.\n14. Impaired cardiac function or clinically significant cardiac disease.\n15. Previous or concurrent malignancy.\n16. Prior organ transplant, or allogeneic hematopoietic stem cell transplantation or recipient of peripheral blood products \\\u003C 3 years prior to TRX319 infusion.\n17. Major surgery within 4 weeks prior or planned within 4 weeks after TRX319 administration.\n18. History of any other neurologic disorder or medical condition the Investigator considers would increase the risk for the participant, including seizure disorders.\n19. Life-threatening allergies, hypersensitivity, or documented intolerance to TRX319 drug product excipients.\n20. Subjects that are pregnant, breast feeding or aim to become pregnant during the study period (Subjects must agree to use a highly effective method of contraception).\n21. Serious and\u002For uncontrolled medical condition that, in the Investigator's judgment, would cause unacceptable safety risk, interfere with study procedures or results, or compromise compliance with the protocol.","65 Years",{"count":163,"type":22},39,[96,67],"The goal of this clinical trial is to treat male and female participants with two types of Multiple Sclerosis (MS) called primary progressive or secondary progressive MS.\n\nThe main questions the trial aims to answer are the following:\n\n* Is TRX319 safe when administered to patients with progressive forms of MS?\n* At what dose does TRX319 work the best to treat participants with primary and or secondary progressive MS?\n* Is pre-conditioning (with Bendamustine) needed to allow TRX319 to better treat participants with primary and\u002For secondary progressive MS?\n\nParticipants will be asked to be on study for up 1 year and may receive up to 3 total administrations of TRX319. While on study, participants will have blood tests and other assessments (MRI scans and lumbar punctures) done to understand the safety of TRX319 and how it may benefit their multiple sclerosis.",[167,168,28,30,31],"Primary Progressive Multiple Sclerosis","Secondary Progressive Multiple Sclerosis (SPMS)",[170,159,171,28,172,173,174,175,176,177,178],"TRX319-01","Tr1X","MS","Autoimmune","Impact MS","PPMS","SPMS","Primary Progressive","Secondary Progressive","2026-03-17",{"date":181,"type":47},"2026-03-19",{"date":183,"type":22},"2026-03",{"date":185,"type":22},"2029-01",{"name":187,"class":188},"Tr1X, Inc.","INDUSTRY",2,{"id":191,"slug":192,"hasResults":11,"nctId":193,"briefTitle":194,"officialTitle":195,"acronym":196,"eligibilityCriteria":197,"healthyVolunteers":11,"sex":17,"minAge":198,"maxAge":199,"enrollmentInfo":200,"targetDuration":4,"studyType":23,"phases":202,"briefSummary":203,"conditions":204,"keywords":206,"overallStatus":143,"whyStopped":4,"lastUpdateSubmitDate":214,"lastUpdatePostDateStruct":215,"startDateStruct":217,"completionDateStruct":219,"leadSponsor":221,"locationsCount":84},"100620266","home-based-functional-balance-intervention-for-multiple-sclerosis-100620266","NCT07355387","Home Based Functional Balance Intervention for Multiple Sclerosis","Home Based Functional Balance Intervention (FBI) for Physical and Cognitive Symptoms of Multiple Sclerosis","HomeFBIinMS","Inclusion Criteria\n\nTelephone Screening Inclusion Criteria:\n\n1. Age 40-90 years.\n2. Self-reported diagnosis of Multiple Sclerosis.\n3. On stable disease-modifying therapy for ≥6 months.\n4. No PT\u002FOT balance-related therapy in the past 6 months.\n5. Able to stand from a chair independently (with or without hand support).\n6. Score 25-75% on the 12-item MS Walking Scale.\n7. No other neurological, cardiopulmonary, musculoskeletal, or systemic conditions affecting standing\u002Fwalking.\n8. English speaking.\n9. Willing to complete all study procedures including Zoom sessions.\n10. Has reliable internet access.\n11. Has a helper buddy available for all sessions.\n12. Possible mild cognitive impairment based on self-report.\n\nInitial Screening Inclusion Criteria:\n\n1. Moderate disability: ePR-EDSS score 4.0-6.5.\n2. Mild cognitive impairment: MoCA 18-25, or Jak\u002FBondi criteria for those scoring 26-30.\n3. Physically inactive or moderately active (Godin score \\\u003C24).\n4. Cardiovascular safety parameters within acceptable limits.\n5. No global aphasia (Mississippi Aphasia Screening Test ≥71 percent).\n6. Berg Balance Scale score ≥40\u002F56.\n7. Able to walk 1 block with or without an assistive device.\n\nHelper Buddy Inclusion Criteria:\n\n1. Age ≥18 years.\n2. Lives within close proximity to the participant.\n3. No self-reported major medical conditions limiting safety assistance.\n4. English speaking.\n5. Able to attend all training and assessment sessions.\n6. Able to assist with basic safety, positioning, and communication with the research team.\n7. Has internet access and can use Zoom.\n\nExclusion Criteria\n\nTelephone Screening Exclusion Criteria:\n\n1. MS relapse or exacerbation within the past 3 months.\n2. Recent major surgery (\\\u003C6 months) or hospitalization (\\\u003C3 months).\n3. Resting shortness of breath or uncontrolled pain \\>3\u002F10.\n4. Uncontrolled hypertension or diabetes.\n5. Bone fracture in the past 6 months.\n6. Disability limiting activities of daily living.\n7. History of epilepsy or uncontrolled seizures in past year.\n8. Sedative medication use that may interfere with training.\n9. Use of Alzheimer's\u002Fdementia-modifying drugs or enrollment in AD clinical trials.\n10. Use of antidepressants or anxiety medications.\n11. Moderate or high risk on PAR-Q (≤1 \"yes\" response).\n12. Severe cognitive impairment (TICS-M ≥18).\n13. Currently receiving cognitive or physical rehabilitation.\n14. Pacemaker use.\n\nInitial Screening Exclusion Criteria:\n\n1. Cardiovascular parameters outside safety limits (HR, BP, O₂ saturation).\n2. Global aphasia (Mississippi \\\u003C71 percent).\n3. Peripheral nerve injury.\n4. Berg Balance Scale \\\u003C40\u002F56.\n5. Inability to walk one block with or without an assistive device.\n\nPopulation Exclusions:\n\n1. Non-English speakers (protocol delivered only in English).\n2. Individuals under 18 years.\n3. Pregnant individuals.\n4. Prisoners or other vulnerable populations.","40 Years","90 Years",{"count":201,"type":22},75,[25],"The study involves a two-arm, Phase 1, randomized controlled clinical trial designed to establish the feasibility and effects of a Functional Balance Intervention (FBI) on physical and cognitive function, as well as measures of daily living among persons with multiple sclerosis (PwMS).\n\nCombined Specific Aims:\n\nAim 1: Examine the effect of the FBI (Intervention Group) on physical function in PwMS compared to a stretching program (Control Group).\n\nHypothesis 1: After four months of training, the FBI group will show significantly greater improvements in physical function compared to the stretching group.\n\nAim 2: Examine the effect of the multicomponent FBI on cognitive function in PwMS compared to the stretching program.\n\nHypothesis 2: After four months of training, the FBI group will show significantly greater improvements in cognitive function compared to the stretching group.\n\nAim 3: Examine the effects of the multicomponent FBI compared to the Control Group among PwMS on measures of daily living (dual-task performance, balance confidence, community mobility, and quality of life).\n\nHypothesis 3: After four months of training, the FBI group will show significantly greater improvements in measures of daily living compared to the stretching group.\n\nAll assessment sessions will be conducted virtually via Zoom. All measures collected during the initial screening, pre-training assessment, training progression, and mid- and post-training assessment sessions will be administered either via Zoom with a Helper Buddy present or through survey links sent to participants via the UIC REDCap system. The training sessions will be performed independently by the participants in the presence of a Helper Buddy.\n\nThe investigators will recruit 75 people with multiple sclerosis (PwMS) for this study. Eligible participants will be randomized to either the FBI (Intervention) or stretching (Control) group, followed by an onboarding session with a designated Helper Buddy. Training will occur twice weekly for four months. Based on the anticipated attrition rate, the investigators aim for 40 PwMS to complete the post-training assessments and finish the study.",[28,29,30,31,205],"Multiple Sclerosis Acute and Progressive",[207,208,28,209,210,211,212,213],"Home based rehabilitation","Telerehabilitation","Mild cognitive impairment","functional balance","safety monitoring","Cognitive motor training","vestibular training","2026-01-12",{"date":216,"type":47},"2026-01-21",{"date":218,"type":47},"2025-11-24",{"date":220,"type":22},"2027-11-24",{"name":222,"class":54},"University of Illinois at Chicago",{"id":224,"slug":225,"hasResults":11,"nctId":226,"briefTitle":227,"officialTitle":228,"acronym":4,"eligibilityCriteria":229,"healthyVolunteers":11,"sex":17,"minAge":230,"maxAge":231,"enrollmentInfo":232,"targetDuration":4,"studyType":23,"phases":234,"briefSummary":235,"conditions":236,"keywords":237,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":239,"lastUpdatePostDateStruct":240,"startDateStruct":242,"completionDateStruct":244,"leadSponsor":246,"locationsCount":84},"100613709","phase-1-senolytics-for-secondary-progressive-ms-100613709","NCT07270120","Senolytics for Secondary Progressive MS","Senolytics to Improve Physical and Cognitive Function in Older Adults With Multiple Sclerosis","Inclusion Criteria:\n\n1. Individuals aged 50-85 with SPMS diagnosed using the 2024 McDonald Criteria\n2. Not treated with a DMT for MS within the last 6 months or have used alemtuzumab, cladribine, or mitoxantrone.\n3. Evidence of MS progression over the past 12 months.\n\nExclusion Criteria:\n\n1. Unstable coronary artery disease (myocardial infarction within 6 months or angina)\n2. Hospitalization within 6 months\n3. Stroke or transient ischemic attack in the past 6 months\n4. Pulmonary arterial hypertension\n5. Current or chronic history of liver disease\n6. Alzheimer's or Parkinson's disease\n7. Drug or alcohol abuse in the previous 5 years\n8. History of coagulation disorders, central nervous system hemorrhage, or gastrointestinal hemorrhage\n9. History of angina or myocardial infarction, arrhythmia, or heart failure at any time\n10. QTc prolongation\n11. Anemia (Hgb\\\u003C9), thrombocytopenia (platelets\\\u003C50,000 per microliter), or neutropenia (ANC\\\u003C 1000 per microliter)\n12. Moderate hypokalemia (2.9 mmol\u002FL) and moderate hypomagnesemia (0.9-1.1 mg\u002FdL or 0.37-0.45 mmol\u002FL)\n13. ALT\u002FAST \\>1.5x ULN, total bilirubin \\>ULN, and alkaline phosphatase \\>2x ULN\n14. Chronic renal disease (glomerular filtration rate \\\u003C 30 mL\u002Fmin\u002F1.73 m2)\n15. Alcohol intake greater than 2 drinks\u002Fday for men and greater than 1 drink\u002Fday for women\n16. Anti-arrhythmic medications known to cause QTc prolongation\n17. Antipsychotics and anxiolytics\n18. Anti-platelet or anti-coagulant medications other than aspirin\n19. Quinolone antibiotics\n20. Pregnant or lactating subjects or subjects intending to become pregnant or to donate egg\u002Fsperm\n21. Participants with p16INK4a below the median of SPMS patients in the OSU Aging and MS Cohort\n22. Use of drugs metabolized by the same liver enzymes as D or Q","50 Years","85 Years",{"count":233,"type":22},30,[96],"This is a clinical trial to see whether senolytic therapy is safe and feasible for patients with secondary progressive MS and whether treatment improves physical and thinking abilities. The study seeks to enroll adults with secondary progressive MS (SPMS), aged 50-85, who are not currently taking a MS disease-modifying therapy and have noticed their MS symptoms getting worse. People who join the study will take the medicines dasatinib and quercetin by mouth every two weeks for three months. These medicines work together to remove old, damaged cells that may cause inflammation and slow the repair of nerves. Participants will also be followed for one year from enrollment to monitor for treatment effects.",[31],[238,71],"senolytic","2025-12-04",{"date":241,"type":47},"2025-12-08",{"date":243,"type":22},"2026-01-15",{"date":245,"type":22},"2028-01-15",{"name":247,"class":54},"Ohio State University",{"id":249,"slug":250,"hasResults":11,"nctId":251,"briefTitle":252,"officialTitle":252,"acronym":4,"eligibilityCriteria":253,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":254,"targetDuration":4,"studyType":256,"phases":4,"briefSummary":257,"conditions":258,"keywords":260,"overallStatus":143,"whyStopped":4,"lastUpdateSubmitDate":263,"lastUpdatePostDateStruct":264,"startDateStruct":266,"completionDateStruct":268,"leadSponsor":270,"locationsCount":84},"100610056","selfie-videos-a-novel-patient-centered-comprehensive-approach-to-measuring-function-in-ms-100610056","NCT07222618","\"Selfie\" Videos: A Novel, Patient-centered, Comprehensive Approach to Measuring Function in MS","Inclusion Criteria:\n\n* Any patient with MS who is above the age of 18 yrs. Participants who are unable to consent for themselves must have a surrogate decision maker or LAR.\n* Age \\> 18 yrs, EDSS - \\\u003C6.5, own a video recording device (smartphone, tablet, camera etc).\n\nExclusion Criteria:\n\n* Patient unwilling to participate in the study. Participants unable to consent for themselves who do not have a surrogate decision maker or LAR.",{"count":255,"type":22},300,"OBSERVATIONAL","The goal of this observational study is to validate a novel, cost-effective method for real-world assessment using patient-acquired \"selfie\" videos in people with multiple sclerosis. The investigators aim to prove the feasibility and validity of monitoring walking changes remotely through a truly patient-centered, low-burden, low-cost approach. The main question this study aims to answer is: do remotely collected walking and speech videos from a mobile phone match the information investigators can gather from an in person visit?\n\nParticipants will collect 5 \"selfie\" videos at baseline, 3 months, 6 months and 12 months (about 15 minutes every 3 months). They will also come in person at baseline, 6 months, and 12 months for in person data collection (about 1 hour per in person visit).",[28,29,30,259,172,31],"MS (Multiple Sclerosis)",[71,172,261,262],"digital tool","UCSF","2025-10-29",{"date":265,"type":47},"2025-10-31",{"date":267,"type":47},"2025-10-01",{"date":269,"type":22},"2028-10-01",{"name":271,"class":54},"University of California, San Francisco"]